J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
An actinium-based backup and Werner helicase inhibitor are notable absences.
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
But the Astra/Daiichi ADC stumbles in lung cancer.
Cafelkibart’s entry into phase 3 is of note to Coherus.
